Anderson Joshua C, Minnich Douglas J, Dobelbower M Christian, Denton Alexander J, Dussaq Alex M, Gilbert Ashley N, Rohrbach Timothy D, Arafat Waleed, Welaya Karim, Bonner James A, Willey Christopher D
The Department of Radiation Oncology, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
The Department of Surgery, Division of Cardiothoracic Surgery, The University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
PLoS One. 2014 Dec 30;9(12):e116388. doi: 10.1371/journal.pone.0116388. eCollection 2014.
Researchers are currently seeking relevant lung cancer biomarkers in order to make informed decisions regarding therapeutic selection for patients in so-called "precision medicine." However, there are challenges to obtaining adequate lung cancer tissue for molecular analyses. Furthermore, current molecular testing of tumors at the genomic or transcriptomic level are very indirect measures of biological response to a drug, particularly for small molecule inhibitors that target kinases. Kinase activity profiling is therefore theorized to be more reflective of in vivo biology than many current molecular analysis techniques. As a result, this study seeks to prove the feasibility of combining a novel minimally invasive biopsy technique that expands the number of lesions amenable for biopsy with subsequent ex vivo kinase activity analysis.
Eight patients with lung lesions of varying location and size were biopsied using the novel electromagnetic navigational bronchoscopy (ENB) technique. Basal kinase activity (kinomic) profiles and ex vivo interrogation of samples in combination with tyrosine kinase inhibitors erlotinib, crizotinib, and lapatinib were performed by PamStation 12 microarray analysis.
Kinomic profiling qualitatively identified patient specific kinase activity profiles as well as patient and drug specific changes in kinase activity profiles following exposure to inhibitor. Thus, the study has verified the feasibility of ENB as a method for obtaining tissue in adequate quantities for kinomic analysis and has demonstrated the possible use of this tissue acquisition and analysis technique as a method for future study of lung cancer biomarkers.
We demonstrate the feasibility of using ENB-derived biopsies to perform kinase activity assessment in lung cancer patients.
研究人员目前正在寻找相关的肺癌生物标志物,以便在所谓的“精准医学”中为患者的治疗选择做出明智的决策。然而,获取足够的肺癌组织进行分子分析存在挑战。此外,目前在基因组或转录组水平对肿瘤进行的分子检测是对药物生物学反应的非常间接的测量,特别是对于靶向激酶的小分子抑制剂。因此,理论上激酶活性分析比许多当前的分子分析技术更能反映体内生物学情况。结果,本研究旨在证明将一种新型微创活检技术与随后的离体激酶活性分析相结合的可行性,该活检技术可扩大适合活检的病变数量。
使用新型电磁导航支气管镜(ENB)技术对8例不同部位和大小的肺部病变患者进行活检。通过PamStation 12微阵列分析对样本进行基础激酶活性(激酶组)分析以及与酪氨酸激酶抑制剂厄洛替尼、克唑替尼和拉帕替尼联合进行离体检测。
激酶组分析定性地确定了患者特异性激酶活性谱以及暴露于抑制剂后激酶活性谱中患者和药物特异性的变化。因此,该研究验证了ENB作为获取足够数量组织进行激酶组分析的方法的可行性,并证明了这种组织获取和分析技术作为未来肺癌生物标志物研究方法的可能用途。
我们证明了使用ENB活检对肺癌患者进行激酶活性评估的可行性。